Added 1 month ago Drug news
FDA approves Adcetris + chemotherapy to treat previously untreated Stage III or IV classical Hodgkin lymphoma.- Seattle Genetics.
Seattle Genetics, Inc. announced that the FDA has approved Adcetris (brentuximab vedotin) in combination with chemotherapy in adult patients with...
Added 2 months ago Drug news
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU)/Rituxan, met its primary...
Added 3 months ago Drug news
FDA accepts filing of Adcetris + chemo to treat advanced classical Hodgkin lymphoma.- Seattle Genetics.
Seattle Genetics, Inc. announced that the FDA has accepted for filing a supplemental Biologics License Application (BLA) for Adcetris (brentuximab...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.
Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
This guideline discusses the investigation and management of patients of all ages with nodular lymphocyte predominant Hodgkin lymphoma...
Added 2 years ago
Guidelines on the management and admission to intensive care of critically ill adult patients with haematological malignancy in the UK
Haem-onc inpatients are at risk of critical illness and should be identified early using NEWS. ICU referral should involve direct discussion between consultant haematologist and consultant intensivist.
Added 2 years ago
The 2014 update elaborates on two histologically distinguished entities: classical Hodgkin's lymphoma that accounts about 95% of cases and nodular lymphocyte-predominant Hodgkin's lymphoma, which represents the remainder of cases.
Added 3 years ago
Background: Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma.
Added 4 months ago
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study.
Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.
Added 7 months ago
Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about their mechanism(s) of action.
Added 10 months ago
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD...
Added 5 months ago
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as...
Added 10 years ago
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
The primary objective for the phase I part of the study is to investigate the safety and tolerability of escalating intravenous (IV) doses of obinutuzumab given as monotherapy...
Added 1 year ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.